Objective To evaluate the use of tryptase in diagnosing allergic diseases.Methods Serum tryptase was measured by Unicap 100 in 35 patients with different types and states of allergic diseases, and 30 healthy volunteers as controls ;Serum tryptases were compared with IgE level.Results Among the 35 allergic patients, 18 cases were with chronic urticaria(4.74?2.54)?g/L; 10 cases had past histories of anaphylaxis shocks(4.86?2.55)?g/L ;7 cases were in acute phase of anaphylaxis(17.4?7.87)?g/L ;30 healthy volunteers(4.36?1.67)?g/L. A statistically significant increase in tryptase concentration was found in patients with acute phase of anaphylaxis compared with other groups.No correlation was found between tryptase concentration and total IgE level.Conclusions Measurement of Serum tryptase level could be an additional tool for diagnosis of anaphylaxis but not chronic urticaria.

OBJECTIVE: To estimate the prevalence of allergic rhinitis (AR) in a community center in Beijing. METHOD: We randomly investigated a community with 13 900 inhabitents in Beijing by means of questionnaire survey. RESULT: A total of 2000 questionnaires was send out, and 1988 of them were collected, which included 952 males and 1036 females (age: 1 to 96 years old, 128 cases are younger than 14 years old. Among of them, 194 cases (9.76%) were diagnosed as having AR according to epidemiologic definition, including 14 children. The prevalence of AR was 9.68% in adults, with male 10.21% and female 9.18%, 10.94% in children. The prevalence in male are slightly higher than in female both with adults and children but without statistic significance. CONCLUSION The survey showed the incidence of AR in Beijing are 9.76% in population, adults 9.68%, children (younger than 12) 10.94%. AR patients are more likely to have other allergic diseases.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Child, Preschool ; China ; epidemiology ; Cities ; epidemiology ; Female ; Humans ; Hypersensitivity ; epidemiology ; Incidence ; Infant ; Male ; Middle Aged ; Prevalence ; Rhinitis, Allergic ; epidemiology ; Sex Distribution ; Surveys and Questionnaires

mended to detect possible leakage of fat within central spinal canal.

Objective To explore the clinicopathological characters of T2 gastric cancer and the value of MSCT in the preop‐erative TNM staging of T2 gastric cancer .Methods A total of 93 patients with T2 gastric cancer were included in our study and un‐derwent preoperative MSCT staging ,who were confirmed by pathologic results .Then the results were compared with those of path‐ologic TNM staging .Also the clinicopathological features of the T2 gastric cancer were analyzed .Results There were no statistical‐ly significant differences in the clinicopathological characters among T2a and T2b patients (P>0 .05) .Comparing with pathologic TNM stage ,the T staging accuracy of MSCT was 91 .40% (85/93) ,the N staging accuracies of CT was 66 .67% (62/93) ,in which , 68 .18% (30/44) ,65 .00% (26/40) ,60 .00% (3/5) and 75 .00% (3/4) were for pN0 ,pN1 ,pN2 and pN3 .And the TNM staging ac‐curacies of CT was 67 .74% (63/93) ,in which ,68 .18% (30/44) ,64 .10% (25/39) ,60 .00% (3/5) and 100% (5/5) were for stageⅠ ,Ⅱ ,Ⅲ and Ⅳ .Conclusion There are no significant different on clinicopathology features among T2a and T2b patients .MSCT can clearly determine the preoperative TNM staging of T2 gastric cancer .

Mast cells are the main effector cells in allergic diseases. Allergic diseases are mostly a direct result of mast cell mediator release effects, while allergen activation is only one of many triggers for mast cell mediator secretion. Increased mast cell number, high mast cell reactivity, or both can lead to abnormal mast cell activation. Mast cell activated syndrome (MCAS) refers to a group or a"spectrum"of mediator-related, symptomatically similar diseases in which mast cells are stimulated by multiple factors. The symptoms and signs of mast cell disease overlap with allergic diseases, but the etiology is different, which requires clinical attention. This article summarizes the research progress on mast cell activation syndrome in recent years thus increase awareness of the differential diagnosis.

The prevalence of allergic diseases has gradually increased worldwide along with the development of industrialization, changes in environmental factors, adjustment of people′s diet structure and increasing exposure to allergens. Allergic diseases have become an important challenge to global public health strategies. Meanwhile, the coexistence with allergic rhinitis, and(or) allergic asthma, and(or) atopic dermatitis and other allergic diseases in a single patient is becoming more and more prevalent. Allergic comorbidities and multimorbidities will inevitably increase the difficulty of treating and recovery, seriously affect patients′ quality of life, and greatly increase the burden on social medical insurance. Understanding the underlying mechanisms of comorbidities and multimorbidities has both preventive and therapeutic significance. This article reviews the research progress of allergy comorbidity and multimorbidity in order to address the importance of this phenominon, stimulate clinical attention and provide a reference for the formulation of prevention and treatment strategies.

Mast cells are the main effector cells in allergic diseases. Allergic diseases are mostly a direct result of mast cell mediator release effects, while allergen activation is only one of many triggers for mast cell mediator secretion. Increased mast cell number, high mast cell reactivity, or both can lead to abnormal mast cell activation. Mast cell activated syndrome (MCAS) refers to a group or a"spectrum"of mediator-related, symptomatically similar diseases in which mast cells are stimulated by multiple factors. The symptoms and signs of mast cell disease overlap with allergic diseases, but the etiology is different, which requires clinical attention. This article summarizes the research progress on mast cell activation syndrome in recent years thus increase awareness of the differential diagnosis.

The prevalence of allergic diseases has gradually increased worldwide along with the development of industrialization, changes in environmental factors, adjustment of people′s diet structure and increasing exposure to allergens. Allergic diseases have become an important challenge to global public health strategies. Meanwhile, the coexistence with allergic rhinitis, and(or) allergic asthma, and(or) atopic dermatitis and other allergic diseases in a single patient is becoming more and more prevalent. Allergic comorbidities and multimorbidities will inevitably increase the difficulty of treating and recovery, seriously affect patients′ quality of life, and greatly increase the burden on social medical insurance. Understanding the underlying mechanisms of comorbidities and multimorbidities has both preventive and therapeutic significance. This article reviews the research progress of allergy comorbidity and multimorbidity in order to address the importance of this phenominon, stimulate clinical attention and provide a reference for the formulation of prevention and treatment strategies.

Objective:To evaluate the diagnostic efficacy and practicality of the Jaundice color card (JCard) as a screening tool for neonatal jaundice.Methods:Following the standards for reporting of diagnostic accuracy studies (STARD) statement, a multicenter prospective study was conducted in 9 hospitals in China from October 2019 to September 2021. A total of 845 newborns who were admitted to the hospital or outpatient department for liver function testing due to their own diseases. The inclusion criteria were a gestational age of ≥35 weeks, a birth weight of ≥2 000 g, and an age of ≤28 days. The neonate′s parents used the JCard to measure jaundice at the neonate′s cheek. Within 2 hours of the JCard measurement, transcutaneous bilirubin (TcB) was measured with a JH20-1B device and total serum bilirubin (TSB) was detected. The Pearson′s correlation analysis, Bland-Altman plots and the receiver operating characteristic (ROC) curve were used for statistic analysis.Results:Out of the 854 newborns, 445 were male and 409 were female; 46 were born at 35-36 weeks of gestational age and 808 were born at ≥37 weeks of gestational age. Additionally, 432 cases were aged 0-3 days, 236 cases were aged 4-7 days, and 186 cases were aged 8-28 days. The TSB level was (227.4±89.6) μmol/L, with a range of 23.7-717.0 μmol/L. The JCard level was (221.4±77.0) μmol/L and the TcB level was (252.5±76.0) μmol/L. Both the JCard and TcB values showed good correlation ( r=0.77 and 0.80, respectively) and agreements (96.0% (820/854) and 95.2% (813/854) of samples fell within the 95% limits of agreement, respectively) with TSB. The JCard value of 12 had a sensitivity of 0.93 and specificity of 0.75 for identifying a TSB ≥205.2?μmol/L, and a sensitivity of 1.00 and specificity of 0.35 for identifying a TSB ≥342.0?μmol/L. The TcB value of 205.2?μmol/L had a sensitivity of 0.97 and specificity of 0.60 for identifying TSB levels of 205.2 μmol/L, and a sensitivity of 1.00 and specificity of 0.26 for identifying TSB levels of 342.0 μmol/L. The areas under the ROC curve (AUC) of JCard for identifying TSB levels of 153.9, 205.2, 256.5, and 342.0 μmol/L were 0.96, 0.92, 0.83, and 0.83, respectively. The AUC of TcB were 0.94, 0.91, 0.86, and 0.87, respectively. There were both no significant differences between the AUC of JCard and TcB in identifying TSB levels of 153.9 and 205.2 μmol/L (both P>0.05). However, the AUC of JCard were both lower than those of TcB in identifying TSB levels of 256.5 and 342.0 μmol/L (both P<0.05). Conclusions:JCard can be used to classify different levels of bilirubin, but its diagnostic efficacy decreases with increasing bilirubin levels. When TSB level are ≤205.2 μmol/L, its diagnostic efficacy is equivalent to that of the JH20-1B. To prevent the misdiagnosis of severe jaundice, it is recommended that parents use a low JCard score, such as 12, to identify severe hyperbilirubinemia (TSB ≥342.0 μmol/L).